Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Abciximab
Drug ID BADD_D00013
Description Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells.
Indications and Usage Abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention and in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours. Abciximab is intended for use with aspirin and heparin and has been studied only in that setting.
Marketing Status approved
ATC Code B01AC13
DrugBank ID DB00054
KEGG ID D02778
MeSH ID D000077284
PubChem ID Not Available
TTD Drug ID D0P3TX
NDC Product Code Not Available
UNII X85G7936GV
Synonyms Abciximab | c7E3 Fab | Chimeric 7E3 Fab | Fab, Chimeric 7E3 | ReoPro | Clotinab | CentoRx
Chemical Information
Molecular Formula Not Available
CAS Registry Number 143653-53-6
SMILES Not Available
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Abscess11.01.08.001--Not Available
Agitation19.06.02.001; 17.02.05.012--
Anaemia01.03.02.001--
Anxiety19.06.02.002--
Arteriovenous fistula24.03.03.001--Not Available
Asthenia08.01.01.001--Not Available
Atrioventricular block02.03.01.002--Not Available
Atrioventricular block complete02.03.01.003--
Back pain15.03.04.005--
Bladder pain20.02.02.001--Not Available
Bradycardia02.03.02.002--Not Available
Bronchitis22.07.01.001; 11.01.09.001--
Bronchospasm22.03.01.004; 10.01.03.012--
Cellulitis23.11.02.004; 11.02.01.001--Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.011--Not Available
Coma17.02.09.001--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Dermatitis bullous23.03.01.002--
Diabetes mellitus05.06.01.001; 14.06.01.001--Not Available
Diarrhoea07.02.01.001--
Diplopia17.17.01.005; 06.02.06.002--Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Dry mouth07.06.01.002--
Dyspepsia07.01.02.001--
Dysuria20.02.02.002--
Gastrooesophageal reflux disease07.02.02.003--
Haemorrhage intracranial24.07.04.003; 17.08.01.008--
The 1th Page    1 2 3    Next   Last    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene